Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.
Conditions
Interventions
Radotinib Hydrochloride
Locations
2
South Korea
Hallym University Sacred Heart Hosptial
Anyang-si, Gyeonnggi-do, South Korea
Keimyung University Daegu Dongsan Hospital
Daegu, South Korea
Start Date
October 24, 2024
Primary Completion Date
September 30, 2026
Completion Date
December 31, 2026
Last Updated
October 30, 2024
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions